# Nobelpharma

Nobelpharma is a Corporate Investor based in Tokyo, Japan.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** 1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033, Japan
- **Founded:** 2003
- **Assets under management:** Undisclosed
- **Website:** nobelpharma.co.jp
- **LinkedIn:** https://linkedin.com/company/ノーベルファーマ（株）

## Regulatory record

- **Reports private funds:** No

## About

Nobelpharma is a pharmaceutical company based in Tokyo, Japan. It develops and delivers drugs and medical devices for diseases affecting small patient populations. Nobelpharma's portfolio includes a range of products, with a focus on expanding its reach to the United States and Europe.

## Sectors

- Pharmaceuticals
- Rare Diseases
- Oncology

## Offices

- Bethesda, MD, USA
- Dusseldorf, Germany
- Taizhou, Jiangsu, China

## People

- Jin Shiomura — Managing Director and CEO

## Questions

### What therapeutic areas does Nobelpharma focus on?

Nobelpharma concentrates on rare and intractable diseases with high unmet medical need. Its portfolio spans oncology, immunology, neurology, and metabolic disorders. The pipeline includes products for pediatric hypophosphatasia and non-muscle-invasive bladder cancer (per the firm, 2023).

### Who are the key strategic partners behind Nobelpharma?

MEDIPAL HOLDINGS CORPORATION is a major shareholder providing distribution and logistics support across Japan. Inabata & Co., Ltd. has been a financial supporter and major shareholder since Nobelpharma's founding in 2003. Hisanaga & Co., Ltd. provides business management services to the group.

### Is Nobelpharma strictly a Japanese company or does it have global operations?

Nobelpharma maintains a global footprint beyond its Tokyo headquarters. It operates a US office in Bethesda, Maryland, a European office in Dusseldorf, Germany, and a manufacturing and development subsidiary in Taizhou, Jiangsu, China. The company sources many of its drug candidates through international licensing deals.

### How does Nobelpharma acquire its drug pipeline?

The firm primarily in-licenses orphan drug candidates from Western biotech and pharmaceutical companies, then conducts clinical development and regulatory work tailored for Asian markets. It also engages in some internal R&D. Notable partnerships include Alexion (Strensiq) and Ferring Pharmaceuticals (Adstiladrin).

## Related profiles

- [Noah Wealth Management](https://altss.com/profile/noah-wealth-management)
- [Noble Foods Group](https://altss.com/profile/noble-foods-group-limited)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nobelpharma

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology